Only in Titles

           Search results for: Polyclonal   

paperclip

#31833228   // Save this To Up

Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells.

The effect of anti-HIV-1 antibodies on complement activation at the surface of infected cells remains partly understood. Here, we show that a subset of anti-Envelope (Env) broadly neutralizing antibodies (bNAbs), targeting the CD4 binding site and the V3 loop, triggers C3 deposition and complement-dependent cytotoxicity (CDC) on Raji cells engineered to express high surface levels of HIV-1 Env. Primary CD4 T cells infected with laboratory-adapted or primary HIV-1 strains and treated with bNAbs are susceptible to C3 deposition but not to rapid CDC. The cellular protein CD59 and viral proteins Vpu and Nef protect infected cells from CDC mediated by bNAbs or by polyclonal IgGs from HIV-positive individuals. However, complement deposition accelerates the disappearance of infected cells within a few days of culture. Altogether, our results uncover the contribution of complement to the antiviral activity of anti-HIV-1 bNAbs.

1573 related Products with: Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells.

Rat monoclonal anti mouse Rat monoclonal anti mouse Signal Transduction Anti Mouse anti human Oncostat Rabbit Anti-Human BAX Ant Rabbit Anti-Human C-Pepti Anti Galectin(Gal-3) Huma Rabbit Anti-Human Vasopre anti-Complement C3 (10A1) Rabbit Anti-Human PAI-1 A Rabbit Anti-Human GHRL An Mouse Anti-Human Fibrobla

Related Pathways

paperclip

#31832521   // Save this To Up

Identification and characterization of the cellular subclones that contribute to the pathogenesis of mantle cell lymphoma.

Mantle cell lymphoma (MCL) is a B-cell malignancy with poor clinical outcome and undefined pathogenesis. Development of clinically relevant cellular models for MCL research is an urgent need. Our preliminary observations lead the development of two novel hypotheses that we tested in this study: 1. multicellular spheroid might be a unique growth mode of early-stage cells in MCL; 2. MCL might be a polyclonal tumor. We made the following original observations that have not been reported: First, we have provided a new experiment method for enriching MCL early-stage cells and characterized the spheroid mode of growth as a unique feature of early-stage MCL cells in cell line as well as in clinical samples. Second, we have established a clinically relevant cellular model of MCL, the cell line, that was highly enriched in early-stage sub-clones. cells and the spheroid growing cells enriched from MCL patients exhibited comparably enhanced tumorigenic abilities and similar biological features. Third, Immunophenotypic analysis has revealed that MCL may be derived from precursor-B(pre-B), immature-B and mature-B cells, not only the mature-B cells as WHO classified in 2016. Fourth, MCL may be a polyclonal disease composed of CD19/IgM, CD19/IgM, CD19/IgM three sub-clones, of which the CD19/IgM sub-clone might be the dominant sub-clone with the strongest tumorigenic ability. Fifth, CD19/IgM that differentiates MCL and normal B cells may represent a new marker for MCL early detection, minor residual disease monitoring after therapies and prognosis.

1408 related Products with: Identification and characterization of the cellular subclones that contribute to the pathogenesis of mantle cell lymphoma.

FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu Tissue array of ovarian g FDA Standard Frozen Tissu Rabbit Anti-Theophylline ELISA TEK™ MBM Thermal CSL Thermal Cycler with C Single Strand DNA Ligase, Recombinant Human PKC the Ofloxacin CAS Number [824 BACTERIOLOGY BACTEROIDES

Related Pathways

paperclip

#31832016   // Save this To Up

PAX8 expression in high-grade serous ovarian cancer positively regulates attachment to ECM via Integrin β3.

Ovarian cancer is the third most common cause of death among gynecologic malignancies worldwide. Understanding the biology and molecular pathogenesis of ovarian epithelial tumors is key to developing improved prognostic indicators and effective therapies. We aimed to determine the effects of PAX8 expression on the migrative, adhesive and survival capabilities of high-grade serous carcinoma cells.

1056 related Products with: PAX8 expression in high-grade serous ovarian cancer positively regulates attachment to ECM via Integrin β3.

High density ovarian canc High density ovarian canc Multiple ovarian cancer t Colon cancer high density High density stomach canc High density colon cancer High density esophageal c Ovarian disease spectrum Small intestine cancer, m Ovarian cancer tissue arr High density cervix cance Head & Neck cancer test t

Related Pathways

paperclip

#31830038   // Save this To Up

Genomes of Leishmania parasites directly sequenced from patients with visceral leishmaniasis in the Indian subcontinent.

Whole genome sequencing (WGS) is increasingly used for molecular diagnosis and epidemiology of infectious diseases. Current Leishmania genomic studies rely on DNA extracted from cultured parasites, which might introduce sampling and biological biases into the subsequent analyses. Up to now, direct analysis of Leishmania genome in clinical samples is hampered by high levels of human DNA and large variation in parasite load in clinical samples. Here, we present a method, based on target enrichment of Leishmania donovani DNA with Agilent SureSelect technology, that allows the analysis of Leishmania genomes directly in clinical samples. We validated our protocol with a set of artificially mixed samples, followed by the analysis of 63 clinical samples (bone marrow or spleen aspirates) from visceral leishmaniasis patients in Nepal. We were able to identify genotypes using a set of diagnostic SNPs in almost all of these samples (97%) and access comprehensive genome-wide information in most (83%). This allowed us to perform phylogenomic analysis, assess chromosome copy number and identify large copy number variants (CNVs). Pairwise comparisons between the parasite genomes in clinical samples and derived in vitro cultured promastigotes showed a lower aneuploidy in amastigotes as well as genomic differences, suggesting polyclonal infections in patients. Altogether our results underline the need for sequencing parasite genomes directly in the host samples.

2793 related Products with: Genomes of Leishmania parasites directly sequenced from patients with visceral leishmaniasis in the Indian subcontinent.

Multiple organ tumor tiss Rat Visceral adipose spec Syringe pump can be contr Thermal Shaker with cooli FDA Standard Frozen Tissu MultiGene Gradient therm FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu Rat monoclonal anti mouse FDA Standard Frozen Tissu

Related Pathways

  •  
  • No related Items
paperclip

#31824502   // Save this To Up

Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.

In the last years, important progresses have been registered in the treatment of patients suffering from oncological/haematological malignancies, but more still needs to be done to reduce toxicity and side effects, improve outcome and offer new strategies for relapsed or refractory disease. A remarkable part of these clinical benefits is due to advances in immunotherapy. Here, we investigate the generation of a novel, universal and ready-to-use immunotherapeutic product based on γδ-T lymphocytes. These cells are part of the innate immune system, exerting potent natural cytotoxicity against bacteria, viruses and tumours. This ability, coupled with their negligible alloreactivity, makes them attractive for adoptive immunotherapy approaches. To achieve a cell product suitable for clinical use, we developed a strategy capable to generate polyclonal γδ-T cells with predominant memory-Vδ1 phenotype in good manufacturing practice (GMP) procedures with the additional possibility of gene-modification to improve their anti-tumour activity. Irradiated, engineered artificial antigen-presenting cells (aAPCs) expressing CD86/41BBL/CD40L and the cytomegalovirus (CMV)-antigen-pp65 were used. The presence of CMV-pp65 and CD40L proved to be crucial for expansion of the memory-Vδ1 subpopulation. To allow clinical translation and guarantee patient safety, aAPCs were stably transduced with an inducible suicide gene. Expanded γδ-T cells showed high expression of activation and memory markers, without signs of exhaustion; they maintained polyclonality and potent anti-tumour activity both (against immortalised and primary blasts) and in studies without displaying alloreactivity signals. The molecular characterisation (phophoproteomic and gene-expression) of these cell products underlines their unique properties. These cells can further be armed with chimeric antigen receptors (CAR) to improve anti-tumour capacity and persistence. We demonstrate the feasibility of establishing an allogeneic third-party, off-the-shelf and ready-to-use, γδ-T-cell bank. These γδ-T cells may represent an attractive therapeutic option endowed with broad clinical applications, including treatment of viral infections in highly immunocompromised patients, treatment of aggressive malignancies refractory to conventional approaches, bridging therapy to more targeted immunotherapeutic approaches and, ultimately, an innovative platform for the development of off-the-shelf CAR-T-cell products.

1430 related Products with: Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells.

Rabbit Anti-GAGE7 Cancer PERMANENT AQUEOUS MOUNTIN RABBIT ANTI GSK3 BETA (pS Polyclonal Antibody Prote anti CD38 Hematopoietic p anti Transferrin receptor Multiple organ cancer tis UniversALL Tissue PCR Kit STAT1 (Phospho Tyr701) An Dog Receptor-binding canc Larynx and pharynx cancer Rectum cancer tissue arra

Related Pathways

paperclip

#31823246   // Save this To Up

Multifaceted antibodies development against synthetic α-dystroglycan mucin glycopeptide as promising tools for dystroglycanopathies diagnostic.

Dystroglycanopathies are diseases characterized by progressive muscular degeneration and impairment of patient's quality of life. They are associated with altered glycosylation of the dystrophin-glycoprotein (DGC) complex components, such as α-dystroglycan (α-DG), fundamental in the structural and functional stability of the muscle fiber. The diagnosis of dystroglycanopathies is currently based on the observation of clinical manifestations, muscle biopsies and enzymatic measures, and the available monoclonal antibodies are not specific for the dystrophic hypoglycosylated muscle condition. Thus, modified α-DG mucins have been considered potential targets for the development of new diagnostic strategies toward these diseases. In this context, this work describes the synthesis of the hypoglycosylated α-DG mimetic glycopeptide NHAc-Gly-Pro-Thr-Val-Thr[αMan]-Ile-Arg-Gly-BSA (1) as a potential tool for the development of novel antibodies applicable to dystroglycanopathies diagnosis. Glycopeptide 1 was used for the development of polyclonal antibodies and recombinant monoclonal antibodies by Phage Display technology. Accordingly, polyclonal antibodies were reactive to glycopeptide 1, which enables the application of anti-glycopeptide 1 antibodies in immune reactive assays targeting hypoglycosylated α-DG. Regarding monoclonal antibodies, for the first time variable heavy (VH) and variable light (VL) immunoglobulin domains were selected by Phage Display, identified by NGS and described by in silico analysis. The best-characterized VH and VL domains were cloned, expressed in E. coli Shuffle T7 cells, and used to construct a single chain fragment variable that recognized the Glycopeptide 1 (GpαDG1 scFv). Molecular modelling of glycopeptide 1 and GpαDG1 scFv suggested that their interaction occurs through hydrogen bonds and hydrophobic contacts involving amino acids from scFv (I51, Y33, S229, Y235, and P233) and R8 and α-mannose from Glycopeptide 1.

1510 related Products with: Multifaceted antibodies development against synthetic α-dystroglycan mucin glycopeptide as promising tools for dystroglycanopathies diagnostic.

Goat Anti-Human, Mouse, R Goat Anti-Human AS160 TBC Peptoid Ligand Assay Deve anti-5Methylcytosine anti Custom Immunoassay Develo Rat monoclonal anti mouse Goat Anti- Cyt19 AS3MT, ( Glucose Assay With the La Astrovirus antibody, Mono Goat Anti-Human ASF1A HSP Cultrex In Vitro Angiogen Goat Anti-Human ASS1 Anti

Related Pathways

  •  
  • No related Items
paperclip

#31818642   // Save this To Up

Functionalization of anti-Brucella antibody based on SNP and MNP nanoparticles for visual and spectrophotometric detection of Brucella.

An Immuno-Nano-Biosensor with high sensitivity was designed based on iron and silica nanoparticles to detect B. abortus. Briefly explain, primary polyclonal antibody (IgG) was conjugated on surface magnetic nanoparticles (MNPs) to form MNP-IgG. Secondary polyclonal antibody (IgG) and Horseradish Peroxidase enzyme were conjugated on silica nanoparticles (SNPs) to form HRP-SNP-IgG. HRP-SNP-IgG. MNP-IgG and HRP-SNP-IgG were added to B. abortus. The MNP-IgG-B.abortus-IgG-SNP-HRP complex was isolated from the reaction mixture using a magnet. After that, tetramethylbenzidine was added to the complex. The reaction was stopped with HCl and investigated using UV-Vis spectrophotometry. The nanoparticles' structure and size were investigated using SEM and DLS. Immuno-Nano-Biosensor sensitivity and specificity were determined. The SEM and DLS results indicated that the SNPs, MNPs, HRP-SNP-IgG and MNP-IgG size and structure were 35, 44, 60 and 56 nm, respectively. In addition, a good linear correlation was observed at 10-10 CFU mL concentrations, which their linear equation and regression were Y = 0.3× + 0.18 and R 0.982, respectively. The limitation of detecting B. abortus was 160 CFU mL. Finally, the results demonstrated that those designed Immuno-Nano-Biosensor could be specifically detected B. abortus and B. melitensis in real samples.

2559 related Products with: Functionalization of anti-Brucella antibody based on SNP and MNP nanoparticles for visual and spectrophotometric detection of Brucella.

Anti-Brucella abortus Ant Anti-Androgen Receptor pr Androgen Receptor Antibod Androgen Receptor Antibod Rabbit Anti-FGF3 Oncogene MOUSE ANTI CANINE DISTEMP MOUSE ANTI BOVINE ROTAVIR Androstenedione-19 Antibo Androgen Receptor (Phosph Anti-daf-2(Abnormal dauer Anti-BMP-1 (Bone Morphoge MOUSE ANTI HUMAN CD19 RPE

Related Pathways

  •  
  • No related Items
paperclip

#31817455   // Save this To Up

Fluorescence Polarization Immunoassay for Determination of Enrofloxacin in Pork Liver and Chicken.

Enrofloxacin (ENR) is a widely used fluoroquinolone (FQ) antibiotic for antibacterial treatment of edible animal. In this study, a rapid and highly specific fluorescence polarization immunoassay (FPIA) was developed for monitoring ENR residues in animal foods. First, ENR was covalently coupled to bovine serum albumin (BSA) to produce specific polyclonal antibodies (pAbs). Three fluorescein-labeled ENR tracers (A, B, and C) with different spacers were synthesized and compared to obtain higher sensitivity. Tracer C with the longest arm showed the best sensitivity among the three tracers. The developed FPIA method showed an IC (50% inhibitory concentration) of 21.49 ng·mL with a dynamic working range (IC-IC) of 4.30-107.46 ng·mL and a limit of detection (LOD, IC) of 1.68 ng·mL. The cross-reactivity (CR) of several structurally related compounds was less than 2%. The recoveries of spiked pork liver and chicken samples varied from 91.3% to 112.9%, and the average coefficients of variation were less than 3.83% and 5.13%, respectively. The immunoassay took only 8 min excluding sample pretreatment. This indicated that the established method had high sensitivity, specificity, and the advantages of simplicity. Therefore, the proposed FPIA provided a useful screening method for the rapid detection of ENR residues in pork liver and chicken.

2038 related Products with: Fluorescence Polarization Immunoassay for Determination of Enrofloxacin in Pork Liver and Chicken.

Liver cancer survey tissu Interleukins Recombinant Liver cancer tissue array Interleukins Recombinant Liver cancer and normal t Liver disease spectrum ti Liver cancer and normal t Colon cancer, metastasize Nile Red, A lipophilic dy Mouse Anti-Chicken Interl Indole 6 carboxaldehyde ( Multiple lung carcinoma (

Related Pathways

paperclip

#31816342   // Save this To Up

Identification of the immunodominant neutralizing regions in the spike glycoprotein of porcine deltacoronavirus.

Porcine deltacoronavirus (PDCoV), is an emerging enteropathogenic coronavirus in pigs, that poses a novel threat to swine husbandry worldwide. Crucial to halting PDCoV transmission and infection is the development of effective therapies and vaccines. The spike (S) protein of coronavirus is the major target of host neutralizing antibodies, however the immunodominant neutralizing region in the S protein of PDCoV has not been defined. Here, three truncations of the PDCoV S protein were generated, the N-terminal domain of the S1 subunit (NTD, amino acids (aa) 50-286), the C-terminal domain of the S1 subunit (CTD, aa 278-616), and S2 subunit (aa 601-1087). The proteins were expressed using an E. coli expression system. Polyclonal antisera against the three recombinant proteins were produced in rabbits and mice. All three antisera were able to inhibit PDCoV infection in vitro, as determined by virus neutralization assay, fluorescent focus neutralization assay, and plaque-reduction neutralization. The CTD-specific antisera had the most potent PDCoV-neutralizing effect, indicating that the CTD region may contain the major neutralizing epitope(s) in the PDCoV S protein. Based on these findings, CTD may be a promising target for development of an effective vaccine against PDCoV infection in pigs.

2667 related Products with: Identification of the immunodominant neutralizing regions in the spike glycoprotein of porcine deltacoronavirus.

FDA Standard Frozen Tissu HIV 1 intergase antigen. MultiGene Gradient therm FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu FDA Standard Frozen Tissu Multiple organ tumor tiss FDA Standard Frozen Tissu Thermal Shaker with cooli Porcine Insulin Sheep Anti-Theophylline 3

Related Pathways

paperclip

#31812660   // Save this To Up

A cocktail of polyclonal affinity enriched antibodies against melanoma mutations increases binding and inhibits tumor growth.

Antibodies that target a single tumor antigen fail to cure stage IV cancer patients due to tumor heterogeneity and variable expression of antigen. Tumor cells with insufficient binding of antibody will not undergo antibody induced cytotoxicity. We describe targeting multiple tumor-specific antigens that resulted in homogeneous dense binding to mouse melanoma cells and significant tumor growth inhibition.

1740 related Products with: A cocktail of polyclonal affinity enriched antibodies against melanoma mutations increases binding and inhibits tumor growth.

Rabbit Anti-Rat Androgen Rat monoclonal anti mouse Rat monoclonal anti mouse Rat monoclonal anti mouse Rat monoclonal anti mouse Rat monoclonal anti mouse Mouse anti human Growth H Antibodies, Rabbit: Rabb Rabbit Anti-Melanoma Mela FDA normal and tumor orga Proteins and Antibodies H Mouse Anti-Human Retinol

Related Pathways